Background:
The t(8;21) abnormality results in an in-frame fusion of an N-terminal domain of the RUNX1 (AML1) and C-terminal domains the RUNX1T1 (ETO). It is found in approximately 5%–10% of all AML cases and can be detected alone or as part of more complex abnormalities. The diagnosis of AML can be made based on this abnormality alone, and it is usually associated with a good prognosis.
Methodology & reporting:
RNA is subjected to cDNA synthesis and quantitative PCR amplification using double-dye oligonucleotide hydrolysis chemistry. The ABL endogenous control transcript is amplified from the sample together with the RUNX1-RUNX1T1 fusion transcript. Standard curves of known amounts of both the endogenous control and the fusion cDNA allow the calculation of the ratio of specific fusion transcript signal to endogenous control gene signal in each sample. Limit of detection for this test is approximately 1 in 100,000 cells.
An interpretive report will be provided.
Effective date: Oct. 1, 2022
Specimen requirement and testing information:
Specimen: 8mL whole blood, or 1 mL bone marrow in EDTA (lavender) tube
Test methodology: QRT-PCR
Test code: T821Q
CPT code: 81401
Turnaround time (TAT):
Stat: 48-72 hours
Routine: 7 days
Stability:
Refrigerated: up to 3 days for blood and 3 days for bone marrow from collection date
Frozen: Not acceptable
Rejection criteria: Gross hemolysis or large blood clots, Specimens that exceed stated stability, unlabeled/mislabeled/mismatched specimens
A summary of all tests offered by our laboratory services can be found here:
http://www.pathology.uci.edu/services/index.asp
Sincerely,
Jeff Chan, MD, PhD
Director
Diagnostic Molecular Pathology Laboratory
Edwin S. Monuki, MD, PhD
Chair
Department of Pathology & Laboratory Medicine
|
